CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Up 391.3% in November

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the target of a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 7,860,000 shares, an increase of 391.3% from the October 31st total of 1,600,000 shares. Currently, 30.0% of the company’s shares are sold short. Based on an average daily volume of 63,190,000 shares, the days-to-cover ratio is presently 0.1 days.

CERo Therapeutics Price Performance

CERO traded down $0.01 during mid-day trading on Friday, hitting $0.19. 6,488,454 shares of the stock were exchanged, compared to its average volume of 20,695,520. The firm’s fifty day moving average is $0.13 and its two-hundred day moving average is $0.29. CERo Therapeutics has a 1-year low of $0.06 and a 1-year high of $12.80.

Insider Transactions at CERo Therapeutics

In related news, major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of the stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $0.10, for a total transaction of $325,000.00. Following the transaction, the insider now owns 22,620,783 shares of the company’s stock, valued at approximately $2,262,078.30. This represents a 12.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Stuart M. Sloan sold 532,486 shares of the stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $0.10, for a total value of $53,248.60. Following the transaction, the insider now directly owns 21,067,956 shares in the company, valued at approximately $2,106,795.60. The trade was a 2.47 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 18.00% of the company’s stock.

CERo Therapeutics Company Profile

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.